Health
A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population, – EurekAlert
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called ”bad” cholesterol–by 50 percent in patients with severe…
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being presented as “late breaking science” at the American Heart Association Scientific Sessions 2020 on Sunday,…
-
General24 hours agoAlleged Croydon Park gunman Artemios Mintzas charged with 25 offences
-
Noosa News10 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
General23 hours agoAn open letter to pro-Palestinian protesters
-
Business12 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400